A Phase 3 interventional study of Ixekizumab and Placebo in Spondylitis, Ankylosing, sponsored by Eli Lilly and Company. Withdrawn at 126 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-16.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Spondylitis, Ankylosing with a site in United States — 10 open to participants now, 13 under way, none of them phase 3. Spondylitis, Ankylosing · United States.
Among the 87 studies in Spondylitis, Ankylosing with a site in United States, this one is the 57th largest by enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2014, is one of 25 in phase 3, and was the 30th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →10 of the 87 studies in Spondylitis, Ankylosing with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18+
University of Central Florida · Sites in United States
Ages 18–65
Brain Inflammation Collaborative · Sites in United States
Ages 2+ · Healthy volunteers
AndHealth · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 19 · Phase 3 25 · Phase 4 3
First in 1995; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 223 across the 59 interventional studies, 445 across the 28 observational. Of the 68 that completed or were terminated, 40 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 87 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
1 of the studies in Spondylitis, Ankylosing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04751396M.D. Anderson Cancer CenterTesting of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors | 2027-02-02 |
Add it to your calendar (.ics) → With an account.
Among the 87 studies in Spondylitis, Ankylosing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active AS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered by 80 milligram (mg) subcutaneous (SC) injection
Drug: Ixekizumab
Administered by 80 mg SC Injection
Drug: Ixekizumab
Placebo for ixekizumab and placebo for adalimumab administered by SC injection
Drug: Placebo
Administered by 40 mg SC injection
Drug: Adalimumab
Administered SC
Also known as: LY2439821
Administered SC
Administered SC
Efficacy of Ixekizumab in Participants with Ankylosing Spondylitis (AS). Measure: Assessment of SpondyloArthritis International Society Criteria (ASAS20)
Time frame: 16 Weeks
Efficacy of Ixekizumab in Participants with AS. Measure: ASAS
Time frame: 16 Weeks
Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)
Time frame: Baseline through 16 Weeks
Efficacy of Ixekizumab in Participants with AS. Measure: Non-Arthritic Disease Assessments
Time frame: Baseline through 16 Weeks
Efficacy of Ixekizumab in Participants with AS. Measure: Peripheral Joint Counts
Time frame: 16 Weeks
Efficacy of Ixekizumab in Participants with AS. Measure: Spinal Mobility
Time frame: Baseline through 16 Weeks
Efficacy of Ixekizumab in Participants with AS. Measure: modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)
Time frame: Baseline through 108 Weeks
Showing the first 100 of 126 sites across 15 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2014, a primary completion of Apr 2016 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab